ArticleEuropean urology open science2022

Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?

Michele Marchioni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.